FDA Clears New ALS Drug for US Market


from BioPharmaDive

The Food and Drug Administration has approved Radicava (edaravone) in the U.S. as the first new drug in two decades to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. This will be marketed by MT Pharma America, a division of Japanese company Mitsubishi Tanabe Pharma.

Read More →

Disclaimer: The viewpoint expressed in this article is the opinion of the author and is not necessarily the viewpoint of the owners or employees at Healthcare Staffing Innovations, LLC.

+ There are no comments

Add yours